drugset
drugset / Trial / NCT00008099

Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer

NCT00008099 ↗

Phase 1 Completed 25 enrolled University of Pittsburgh National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with resected or locally advanced unresectable pancreatic cancer.

Timeline

Start
1998-05
Primary completion
2001-03
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject MUC1 antigen Unknown — Intramuscular
Background SB-AS2 Unknown — Intramuscular

Indications

malignant pancreatic neoplasm